TP53 mutations are frequently observed in diffuse large B-cell lymphoma (DLBCL) and refractory/relapsed aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL), where they are strongly associated with poor prognosis, treatment resistance, and relapse (17). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.